Edition:
United States

Keryx Biopharmaceuticals Inc (KERX.OQ)

KERX.OQ on NASDAQ Stock Exchange Capital Market

5.01USD
15 Jun 2018
Change (% chg)

$-0.04 (-0.79%)
Prev Close
$5.05
Open
$5.01
Day's High
$5.12
Day's Low
$5.01
Volume
1,480,212
Avg. Vol
300,701
52-wk High
$8.37
52-wk Low
$3.92

Chart for

About

Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally... (more)

Overall

Beta: 2.58
Market Cap(Mil.): $603.84
Shares Outstanding(Mil.): 120.53
Dividend: --
Yield (%): --

Financials

  KERX.OQ Industry Sector
P/E (TTM): -- 240.92 34.18
EPS (TTM): -2.34 -- --
ROI: -272.96 -5.87 13.17
ROE: -- -7.71 15.15

BRIEF-Keryx Biopharmaceuticals Reports Q1 Loss Per Share Of $0.18

* KERYX BIOPHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

May 10 2018

BRIEF-Keryx Biopharmaceuticals Sees Total Revenue For Qtr Ended March 31, 2018 Between $21.0 Mln And $22.5 Mln

* KERYX BIOPHARMACEUTICALS SEES TOTAL REVENUE FOR QUARTER ENDED MARCH 31, 2018 OF BETWEEN $21.0 MILLION AND $22.5 MILLION - SEC FILING

Apr 30 2018

BRIEF-Keryx Biopharmaceuticals Q4 Loss Per Share $0.26

* KERYX BIOPHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Feb 07 2018

BRIEF-Keryx Biopharma Says Norwich Pharmaceuticals Agreed To Terminate Manufacturing Services Agreement

* KERYX BIOPHARMACEUTICALS- ON DEC 20,CO,NORWICH PHARMACEUTICALS AGREED TO TERMINATE MANUFACTURING SERVICES AGREEMENT BETWEEN CO,NPI,DATED JAN 17, 2014‍​

Dec 27 2017

Competitors

  Price Chg
Sanofi SA (SASY.PA) €68.68 +1.35
Fresenius Medical Care AG & Co. KGaA (FMEG.DE) €87.76 -0.72
Shire PLC (SHP.L) 4,037.50 -32.00
Shire PLC (3159084.L) -- --

Earnings vs. Estimates